How Many Inogen, Inc. (NASDAQ:INGN)’s Analysts Are Bullish?

May 16, 2018 - By Stephen Andrade

Inogen, Inc. (NASDAQ:INGN) LogoInvestors sentiment decreased to 1.18 in 2017 Q4. Its down 0.02, from 1.2 in 2017Q3. It dived, as 19 investors sold Inogen, Inc. shares while 68 reduced holdings. 37 funds opened positions while 66 raised stakes. 20.27 million shares or 1.65% less from 20.61 million shares in 2017Q3 were reported.
National Bank Of America Corp De holds 0% or 28,706 shares. Manufacturers Life Ins The holds 13,027 shares or 0% of its portfolio. Ahl Prtnrs Llp holds 0.05% in Inogen, Inc. (NASDAQ:INGN) or 26,473 shares. Oppenheimer And holds 8,400 shares. Thornburg Invest Mgmt accumulated 53,354 shares or 0.04% of the stock. Invesco Ltd holds 216,018 shares. Arrowstreet Cap Partnership stated it has 11,800 shares or 0% of all its holdings. Acadian Asset Mgmt Lc stated it has 6,980 shares. Northwestern Mutual Wealth Mngmt Com has 17 shares. 383,362 were accumulated by State Common Retirement Fund. Bancorporation Of Ny Mellon Corporation has 283,315 shares for 0.01% of their portfolio. Fuller And Thaler Asset Mngmt holds 0.11% or 74,390 shares. Fred Alger Management owns 248,232 shares. Swiss Natl Bank invested in 0% or 30,500 shares. Atika Capital Management Ltd Liability Corporation reported 21,000 shares stake.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

Among 5 analysts covering Inogen (NASDAQ:INGN), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inogen had 7 analyst reports since February 20, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Tuesday, February 20 by PiperJaffray. As per Tuesday, May 1, the company rating was maintained by Needham. The company was maintained on Tuesday, May 1 by J.P. Morgan. Needham maintained the stock with “Buy” rating in Wednesday, February 28 report. Piper Jaffray upgraded the shares of INGN in report on Tuesday, February 20 to “Buy” rating. Needham maintained Inogen, Inc. (NASDAQ:INGN) rating on Friday, April 13. Needham has “Buy” rating and $15000 target. JP Morgan maintained it with “Overweight” rating and $180 target in Tuesday, May 1 report. Below is a list of Inogen, Inc. (NASDAQ:INGN) latest ratings and price target changes.

01/05/2018 Broker: J.P. Morgan Rating: Buy New Target: $180.0000 Maintain
01/05/2018 Broker: Needham Rating: Buy New Target: $215.0000 Maintain
01/05/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $150 New Target: $180 Maintain
13/04/2018 Broker: Needham Rating: Buy New Target: $150.0000 Maintain
28/02/2018 Broker: Needham Rating: Buy New Target: $150.0 Maintain
20/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
20/02/2018 Broker: Piper Jaffray Rating: Buy Upgrade

The stock increased 2.33% or $4.15 during the last trading session, reaching $182.15. About 96,349 shares traded. Inogen, Inc. (NASDAQ:INGN) has risen 59.63% since May 16, 2017 and is uptrending. It has outperformed by 48.08% the S&P500.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $3.87 billion. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 189.74 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

More notable recent Inogen, Inc. (NASDAQ:INGN) news were published by: Streetinsider.com which released: “Pre-Open Movers 05/01: (INGN) (KPTI) (NTRI) Higher; (IVAC) (CGNX) (KLXI) Lower (more…)” on May 01, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” published on May 10, 2018, Businesswire.com published: “Inogen Announces Record First Quarter 2018 Financial Results and Increases 2018 Guidance” on April 30, 2018. More interesting news about Inogen, Inc. (NASDAQ:INGN) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Lower; Pfizer Posts Mixed Q1 Results” published on May 01, 2018 as well as Seekingalpha.com‘s news article titled: “Inogen’s (INGN) CEO Scott Wilkinson on Q1 2018 Results – Earnings Call Transcript” with publication date: April 30, 2018.

Inogen, Inc. (NASDAQ:INGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com